Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Efficacy and NSAID-sparing in Ankylosing Spondylitis (ASTRUM)
NCT02763046Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2016
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Started May 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02763046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763046.